 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 June 1995 | Volume 122 Issue 11 | Pages 856-866
Purpose: To do a meta-analysis on the efficacy of early or deferred zidovudine monotherapy in patients with human immunodeficiency virus (HIV) infection but not the acquired immunodeficiency syndrome (AIDS).
Data Sources: Articles on zidovudine monotherapy published through May 1994.
Study Selection: Double-blind, randomized, placebo-controlled trials addressing the efficacy of zidovudine monotherapy in HIV-infected persons without an AIDS-defining illness.
Data Extraction: Progression to any primary trial end point; any clinical end point; and AIDS or death. Data were stratified according to disease stage at study entry and duration of follow-up (short-term, <14 months; long-term, >21 months).
Data Synthesis: Early initiation of zidovudine therapy was of short-term benefit for all the end points evaluated (for example, the risk ratio for progression to any primary end point was 0.51; 95% CI, 0.41 to 0.64). Long-term trials showed a marginally significant trend of decreased progression to any primary end point (risk ratio, 0.73; CI, 0.52 to 1.03). The trend was not significant for other end points. With further stratification according to disease stage, progression to AIDS or death in the short term was significantly decreased for both symptomatic and asymptomatic patients with CD4 cell counts of less than 500 x 106/L (risk ratios, 0.26 [CI, 0.13 to 0.56] and 0.43 [CI, 0.30 to 0.64], respectively). A regression analysis indicated a larger relative benefit in short-term trials and symptomatic patients than in long-term trials and asymptomatic patients.
Conclusions: Early initiation of zidovudine therapy offers a benefit that decreases over time. Symptomatic patients experience a larger benefit than asymptomatic patients. The implications beyond 3 years of follow-up remain unknown.
Author and Article Information
From Tufts University School of Medicine and New England Medical Center Hospitals, Boston, Massachusetts; and Mount Sinai School of Medicine, New York, New York.
REVIEW
Early or Deferred Zidovudine Therapy in HIV-Infected Patients without an AIDS-Defining Illness
A Meta-Analysis
Requests for Reprints: Joseph Lau, MD, Division of Clinical Care Research, New England Medical Center, Box 63, 750 Washington Street, Boston, MA 02111.
This article has been cited by other articles:
|
|
 |
|
  D. Mauri, N. Pavlidis, N. P. Polyzos, and J. P. A. Ioannidis Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst, September 20, 2006; 98(18): 1285 - 1291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lau, J. P A Ioannidis, N. Terrin, C. H Schmid, and I. Olkin The case of the misleading funnel plot BMJ, September 16, 2006; 333(7568): 597 - 600. [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. A. Ioannidis Contradicted and Initially Stronger Effects in Highly Cited Clinical Research JAMA, July 13, 2005; 294(2): 218 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. Ko, P. R. Hebert, C. S. Coffey, J. P. Curtis, J. M. Foody, A. Sedrakyan, and H. M. Krumholz Adverse Effects of {beta}-Blocker Therapy for Patients With Heart Failure: A Quantitative Overview of Randomized Trials Arch Intern Med, July 12, 2004; 164(13): 1389 - 1394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. T. Ko, P. R. Hebert, C. S. Coffey, A. Sedrakyan, J. P. Curtis, and H. M. Krumholz {beta}-Blocker Therapy and Symptoms of Depression, Fatigue, and Sexual Dysfunction JAMA, July 17, 2002; 288(3): 351 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Jordan, L. Gold, C. Cummins, and C. Hyde Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy BMJ, March 30, 2002; 324(7340): 757 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Freemantle, J. Cleland, P. Young, J. Mason, and J. Harrison beta Blockade after myocardial infarction: systematic review and meta regression analysis BMJ, June 26, 1999; 318(7200): 1730 - 1737. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Baldeweg, J. Catalan, and B. G Gazzard Risk of HIV dementia and opportunistic brain disease in AIDS and zidovudine therapy J. Neurol. Neurosurg. Psychiatry, July 1, 1998; 65(1): 34 - 41. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. D. Kemp, C. Shi, S. Bloor, P. R. Harrigan, J. W. Mellors, and B. A. Larder A Novel Polymorphism at Codon 333 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Can Facilitate Dual Resistance to Zidovudine and L-2',3'-Dideoxy-3'-Thiacytidine J. Virol., June 1, 1998; 72(6): 5093 - 5098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Eccles, N. Freemantle, and J. Mason North of England evidence based guidelines development project: methods of developing guidelines for efficient drug use in primary care BMJ, April 18, 1998; 316(7139): 1232 - 1235. [Full Text]
|
|
|
|
|
|
J. P. A. Ioannidis Effect of the Statistical Significance of Results on the Time to Completion and Publication of Randomized Efficacy Trials JAMA, January 28, 1998; 279(4): 281 - 286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A Engels, M. E Falagas, J. Lau, and M. L Bennish Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity BMJ, January 10, 1998; 316(7125): 110 - 116. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. J. Eron, S. L. Benoit, J. Jemsek, R. D. MacArthur, J. Santana, J. B. Quinn, D. R. Kuritzkes, M. A. Fallon, M. Rubin, and The North American HIV Working Party Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter N. Engl. J. Med., December 21, 1995; 333(25): 1662 - 1669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Early vs. Delayed AZT: A Meta-Analysis AIDS Clinical Care, August 1, 1995; 1995(801): 6 - 6. [Full Text]
|
|
Article
